Durvalumab plus chemotherapy in ES-SCLC (Oriental)

Study identifier:D419BR00018

ClinicalTrials.gov identifier:NCT04449861

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open Label, Multicenter Study of First-Line Durvalumab plus Platinum-Based Chemotherapy in Chinese Patients with Extensive Stage Small-Cell Lung Cancer (Oriental)

Medical condition

Small Cell Lung Carcinoma Extensive Disease

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab plus chemotherapy

Sex

All

Actual Enrollment

166

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 07 Dec 2020
Primary Completion Date: 30 Mar 2023
Study Completion Date: 30 Mar 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria